Author:
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Gardner CL, Ryman KD, 2010. Yellow fever: a reemerging threat. Clin Lab Med 30: 237–260.
-
2.
Monath TP, Vasconcelos PF, 2015. Yellow fever. J Clin Virol 64: 160–173.
-
3.
World Health Organization , 2019. Yellow Fever Situation Report. Available at: https://www.who.int/en/news-room/fact-sheets/detail/yellow-fever. Accessed September 24, 2020.
-
4.
Thomas RE, 2016. Yellow fever vaccine-associated viscerotropic disease: current perspectives. Drug Des Devel Ther 10: 3345–3353.
-
5.
da Saúde Brasil Ministério, em Saúde Secretaria de Vigilância, Epidemiológica Departamento de Vigilância, 2020. Manual de Vigilância Epidemiológica de Eventos Adversos Pós-Vacinação, 4th edition. Brasília, Brazil: Ministério da Saúde.
-
6.
Martins RM et al., 2014. Adverse events following yellow fever immunization: report and analysis of 67 neurological cases in Brazil. Vaccine 32: 6676–6682.
-
7.
O’Grady JG, Alexander GJ, Hayllar KM, Williams R, 1989. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97: 439–445.
-
8.
Mantel N, Aguirre M, Gulia S, Girerd-Chambaz Y, Colombani S, Moste C, Barban V, 2008. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 151: 40–46.
-
9.
Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T, 2011. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 29: 4544–4555.
-
10.
Lindsey NP, Rabe IB, Miller ER, Fischer M, Staples JE, 2016. Adverse events reports following yellow fever vaccination, 2007–13. J Travel Med 23: 1–6.
-
11.
Martins RM, Leal MLF, Homma A, 2015. Serious adverse events associated with yellow fever vaccine. Hum Vaccin Immunother 11: 2183–2187.
-
12.
Gershman MD et al., 2012. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 30: 5038–5058.
-
13.
Kohl KS et al., 2007. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine 25: 5671–5674.
-
14.
Seligman SJ, 2011. Yellow fever virus vaccine-associated deaths in young women 1891–1893. Emerg Infect Dis 17: 1891–1893.
-
15.
Whittemburry A et al., 2009. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 27: 5974–5981.
-
16.
Pan American Health Organization , 2013. Viscerotropic Disease Associated with Yellow Fever: Case Studies. Washington, DC: PAHO.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 3118 | 1673 | 79 |
| Full Text Views | 350 | 23 | 2 |
| PDF Downloads | 219 | 25 | 0 |
Case Report: Fatal Viscerotropic Disease in a Young Woman Following Yellow Fever Vaccination
Mariângela Ottoboni Brunaldi
Mariângela Ottoboni Brunaldi
Department of Pathology and Forensic Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil;
Search for other papers by Mariângela Ottoboni Brunaldi in
Current site
Google Scholar
PubMed
Search for other papers by Mariângela Ottoboni Brunaldi in
Current site
Google Scholar
PubMed
René Julias Costa Silva
René Julias Costa Silva
Department of Pathology and Forensic Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil;
Search for other papers by René Julias Costa Silva in
Current site
Google Scholar
PubMed
Search for other papers by René Julias Costa Silva in
Current site
Google Scholar
PubMed
Alexandre Todorovic Fabro
Alexandre Todorovic Fabro
Department of Pathology and Forensic Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil;
Search for other papers by Alexandre Todorovic Fabro in
Current site
Google Scholar
PubMed
Search for other papers by Alexandre Todorovic Fabro in
Current site
Google Scholar
PubMed
Daniel Cardoso de Almeida e Araujo
Daniel Cardoso de Almeida e Araujo
Division of Epidemiological Surveillance, Secretaria Municipal de Saúde, Ribeirão Preto, São Paulo, Brazil;
Search for other papers by Daniel Cardoso de Almeida e Araujo in
Current site
Google Scholar
PubMed
Search for other papers by Daniel Cardoso de Almeida e Araujo in
Current site
Google Scholar
PubMed
Anibal Basile-Filho
Anibal Basile-Filho
Division of Intensive Care Medicine, Department of Surgery and Anatomy, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil;
Search for other papers by Anibal Basile-Filho in
Current site
Google Scholar
PubMed
Search for other papers by Anibal Basile-Filho in
Current site
Google Scholar
PubMed
Maria Auxiliadora-Martins
Maria Auxiliadora-Martins
Division of Intensive Care Medicine, Department of Surgery and Anatomy, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil;
Search for other papers by Maria Auxiliadora-Martins in
Current site
Google Scholar
PubMed
Search for other papers by Maria Auxiliadora-Martins in
Current site
Google Scholar
PubMed
Mayra Gonçalves Menegueti
Mayra Gonçalves Menegueti
Division of Intensive Care Medicine, Department of Surgery and Anatomy, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil;
Search for other papers by Mayra Gonçalves Menegueti in
Current site
Google Scholar
PubMed
Search for other papers by Mayra Gonçalves Menegueti in
Current site
Google Scholar
PubMed
Maria Isabel Beloddi
Maria Isabel Beloddi
Division of Intensive Care Medicine, Department of Surgery and Anatomy, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil;
Search for other papers by Maria Isabel Beloddi in
Current site
Google Scholar
PubMed
Search for other papers by Maria Isabel Beloddi in
Current site
Google Scholar
PubMed
Danillo Lucas Alves Esposito
Danillo Lucas Alves Esposito
Infectious Diseases Division, Department of Internal Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil
Search for other papers by Danillo Lucas Alves Esposito in
Current site
Google Scholar
PubMed
Search for other papers by Danillo Lucas Alves Esposito in
Current site
Google Scholar
PubMed
Benedito Antônio Lopes da Fonseca
Benedito Antônio Lopes da Fonseca
Infectious Diseases Division, Department of Internal Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil
Search for other papers by Benedito Antônio Lopes da Fonseca in
Current site
Google Scholar
PubMed
Search for other papers by Benedito Antônio Lopes da Fonseca in
Current site
Google Scholar
PubMed
ABSTRACT.
Yellow fever is a viral hemorrhagic disease, and vaccination is the most effective way to minimize the impact of the disease. Serious adverse events after yellow fever vaccination are rare. We report the case of a young woman with an unusual presentation of yellow fever 17DD vaccine-associated acute viscerotropic disease, with severe hepatic impairment following a long incubation period. She died more than a month after yellow fever vaccination.
Author Notes
Financial support: This work was supported by São Paulo Research Foundation (FAPESP-N°2003/07959-0).
Authors’ addresses: Mariângela Ottoboni Brunaldi, René Julias Costa Silva, and Alexandre Todorovic Fabro, Department of Pathology and Forensic Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil, E-mails: mabrunaldi@fmrp.usp.br, renejulias@yahoo.com.br, and fabro@fmrp.usp.br. Daniel Cardoso de Almeida e Araujo, Division of Epidemiological Surveillance, Secretaria Municipal de Saúde, Ribeirão Preto, São Paulo, Brazil, E-mail: dacaraujo@alumni.usp.br. Anibal Basile-Filho, Maria Auxiliadora-Martins, Mayra Gonçalves Menegueti, and Maria Isabel Beloddi, Division of Intensive Care Medicine, Department of Surgery and Anatomy. University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil, E-mails: abasile@fmrp.usp.br, mamartins@hcrp.usp.br, mayramenegueti@usp.br, and bel_ft@yahoo.com.br. Danillo Lucas Alves Esposito and Benedito Antônio Lopes da Fonseca, Infectious Diseases Division, Department of Internal Medicine, University Hospital, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão Preto, São Paulo, Brazil, E-mails: esposito@usp.br and bfonseca@usp.br.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Gardner CL, Ryman KD, 2010. Yellow fever: a reemerging threat. Clin Lab Med 30: 237–260.
-
2.
Monath TP, Vasconcelos PF, 2015. Yellow fever. J Clin Virol 64: 160–173.
-
3.
World Health Organization , 2019. Yellow Fever Situation Report. Available at: https://www.who.int/en/news-room/fact-sheets/detail/yellow-fever. Accessed September 24, 2020.
-
4.
Thomas RE, 2016. Yellow fever vaccine-associated viscerotropic disease: current perspectives. Drug Des Devel Ther 10: 3345–3353.
-
5.
da Saúde Brasil Ministério, em Saúde Secretaria de Vigilância, Epidemiológica Departamento de Vigilância, 2020. Manual de Vigilância Epidemiológica de Eventos Adversos Pós-Vacinação, 4th edition. Brasília, Brazil: Ministério da Saúde.
-
6.
Martins RM et al., 2014. Adverse events following yellow fever immunization: report and analysis of 67 neurological cases in Brazil. Vaccine 32: 6676–6682.
-
7.
O’Grady JG, Alexander GJ, Hayllar KM, Williams R, 1989. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97: 439–445.
-
8.
Mantel N, Aguirre M, Gulia S, Girerd-Chambaz Y, Colombani S, Moste C, Barban V, 2008. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 151: 40–46.
-
9.
Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T, 2011. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 29: 4544–4555.
-
10.
Lindsey NP, Rabe IB, Miller ER, Fischer M, Staples JE, 2016. Adverse events reports following yellow fever vaccination, 2007–13. J Travel Med 23: 1–6.
-
11.
Martins RM, Leal MLF, Homma A, 2015. Serious adverse events associated with yellow fever vaccine. Hum Vaccin Immunother 11: 2183–2187.
-
12.
Gershman MD et al., 2012. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 30: 5038–5058.
-
13.
Kohl KS et al., 2007. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine 25: 5671–5674.
-
14.
Seligman SJ, 2011. Yellow fever virus vaccine-associated deaths in young women 1891–1893. Emerg Infect Dis 17: 1891–1893.
-
15.
Whittemburry A et al., 2009. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 27: 5974–5981.
-
16.
Pan American Health Organization , 2013. Viscerotropic Disease Associated with Yellow Fever: Case Studies. Washington, DC: PAHO.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 3118 | 1673 | 79 |
| Full Text Views | 350 | 23 | 2 |
| PDF Downloads | 219 | 25 | 0 |